Peng Kuan – HKU COVID-19 Digital Archives

Peng Kuan

DEPT

Department of Pharmacology and Pharmacy

FACULTY

Li Ka Shing Faculty of Medicine

COVID-19 Contribution

Showing 1 - 5 out of 5

Show

Relevance

01 Mar 2023
Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)
L
Li, X
P
Peng, K
C
Cheng, FWT
L
Lam, CLD
C
Cheung, CL
C
Chui, SLC
L
Lai, TTF
W
Wan, YFE
W
Wong, CKH
M
Ma, T
Y
Yum, SHH
C
Chan, EWY
H
Huang, J
L
Lau, WCS
I
Ip, MSM
W
Wong, ICK
Coronavirus vaccines Innate immunity Tuberculosis
01 Sep 2023
Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study
Background Case reports suggest that SARS-CoV-2 infection could lead to immune dysregulation and trigger autoimmunity while COVID-19 vaccination is ef...Read more
P
Peng, K
L
Li, X
Y
Yang, D
C
Chan, CWS
Z
Zhou, J
W
Wan, YFE
C
Chui, SLC
L
Lai, TTF
W
Wong, CKH
C
Chan, EWY
L
Leung, WK
L
Lau, WCS
W
Wong, ICK
Autoimmune disorders Coronavirus vaccines SARS
25 Jan 2022
Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine
Background: Case reports of carditis after BNT162b2 vaccination are accruing worldwide. Objective: To examine the association of BNT162b2 and Coron...Read more
L
Lai, TTF
L
Li, X
P
Peng, K
H
Huang, L
I
Ip, P
T
Tong, X
W
Wan, YFE
W
Wong, CKH
C
Chan, EWY
S
Siu, DCW
W
Wong, ICK
01 Jun 2022
Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
Background: Post-marketing pharmacovigilance data are scant on the safety of Covid-19 vaccines among people with previous SARS-CoV-2 infection compare...Read more
L
Lai, TTF
H
Huang, L
P
Peng, K
L
Li, X
C
Chui, SLC
W
Wan, YFE
W
Wong, CKH
C
Chan, EWY
H
Hung, FNI
W
Wong, ICK
01 Mar 2022
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
Objective: CoronaVac (Sinovac) Covid-19 vaccine has recently been approved for emergency use by the World Health Organization. However, data on its re...Read more
L
Lai, TTF
L
Leung, TYM
C
Chan, EWW
H
Huang, L
L
Lau, L
P
Peng, K
F
Fan, M
C
Chen, K
L
Li, X
C
Chui, SLC
W
Wan, YFE
W
Wong, CKH
C
Cowling, BJ
W
Wong, ICK
C
Chan, EWY

01 Mar 2023

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)

01 Sep 2023

Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study

25 Jan 2022

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine

01 Jun 2022

Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection

01 Mar 2022

Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring

Site Map

About

Policy

Copyright © 2023 - University Libraries, The University of Hong Kong